Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.


Issue 9, 2018
Previous Article Next Article

Design, synthesis, and evaluation of 4,5,6,7-tetrahydrobenzo[d]thiazole-based novel dual kinase inhibitors of CK2 and GSK3β

Author affiliations

Abstract

Casein kinase 2 (CK2) and glycogen synthase kinase-3beta (GSK3β) are responsible for the phosphorylation of a tumor suppressor protein (PTEN) in a cooperative manner which causes its deactivation. Thus, it is essential to inhibit both kinases simultaneously to prevent PTEN deactivation more efficiently. In this study, we have designed a novel lead from Hit15 which was identified in silico as a dual kinase inhibitor against CK2 and GSK3β through our previous study. The dataset of structural analogs of the lead was designed and confirmed by pharmacophore mapping and molecular docking. The screened analogs were considered further and a series of “tetrahydrobenzo[d]thiazoles” were synthesized. Compound 1g has shown highest dual kinase inhibitory activity at a concentration of 1.9 μM against CK2 and 0.67 μM against GSK3β. Our results suggest that the presence of a carboxyl group at the meta position of the phenyl ring plays a vital role in dual kinase inhibition.

Graphical abstract: Design, synthesis, and evaluation of 4,5,6,7-tetrahydrobenzo[d]thiazole-based novel dual kinase inhibitors of CK2 and GSK3β

Back to tab navigation

Supplementary files

Article information


Submitted
28 Jun 2018
Accepted
25 Jul 2018
First published
26 Jul 2018

Med. Chem. Commun., 2018,9, 1472-1490
Article type
Research Article

Design, synthesis, and evaluation of 4,5,6,7-tetrahydrobenzo[d]thiazole-based novel dual kinase inhibitors of CK2 and GSK3β

T. R. Pardhi, M. S. Patel, V. Sudarsanam and K. K. Vasu, Med. Chem. Commun., 2018, 9, 1472
DOI: 10.1039/C8MD00321A

Search articles by author

Spotlight

Advertisements